Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma

Drug Profile

Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma

Alternative Names: Aemcolo; CB-01-11; Rifamycin controlled release; Rifamycin CR; Rifamycin SV; Rifamycin SV MMX

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Dr Falk Pharma; Salix Pharmaceuticals
  • Class Antibacterials; Antirheumatics; Antituberculars; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Traveller's diarrhoea
  • Phase II Diverticulitis
  • No development reported Diarrhoea

Most Recent Events

  • 30 Oct 2017 Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma receives Fast Track designation for Traveller's diarrhoea [PO,Controlled release] in USA
  • 30 Oct 2017 Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma receives Qualified Infectious Disease Product status for Traveller's diarrhoea in USA
  • 01 Jul 2017 Dr. Falk Pharma completes a phase II trial for Diverticulitis in Germany (NCT01847664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top